Introducing Precision Therapeutics
But most patients recieve a combination of chemotherapy, radiation, immunotherapy, and surgery. Precision medicine takes into account individual variability in genes, mutations, environment and lifestyle to introduce targeted therapies, some with companion diagnostic tests that identify patients most likely to benefit from a particular treatment.
Precision Therapeutics is advancing the frontiers of this rapidly growing field of medicine. Our breakthroughs in sophisticated gene, protein, and bioinfomatics techniques mean we can view the intricate interplay between the genes and regulatory factors responsible for cancers.
With artificial intelligence, the D-CHIP™ platform continously learns from each patient, creating a valuable knowledge base of tumor profiles and drug responses that can be used by our partners to develop the next generation of diagnostics and therapies.
Through its partnership with Helomics, Precision Therapeutics has also founded Tumorgenesis™ Incorporated. Its scientists hope to develop an innovative, rapid approach to growing laboratory tumors that effectively "fool" cancer cells into thinking they are growing inside a human body. These lab-grown models will be used to test drugs for personalized therapy and to develop new drugs.
Dr. Schwartz was appointed to Skyline Medical's board of directors in March 2016, and became interim president and CEO in May 2016. He has owned and managed dental groups in Michigan, beginning with one practice in 1966, and overseeing its expansion into a 14-office practice when he left the active practice of dentistry in 1988. He currently owns two dental practices in Burton, Mich. and Grand Blanc, Mich.
In 1988 Dr. Schwartz joined a family business, becoming CEO of Plastics Research Corporation, a Flint, Mich. manufacturer of structural foam molding, a low pressure injection molding process. While there he led its growth from $2 mm in revenues and 20 employees, to it becoming the largest manufacturer of structural foam molding products under one roof in the US with more than $60 million in revenues and 300 employees when he retired in 2001. He holds a BA and a DDS degrees from the University of Detriot.
Mr. Myers was appointed CFO and Secretary in 2012. He has over 30 years experience in multiple industries focusing on medical device, service and manufacturing. He has spent much of his career as a CFO and Controller. A public accountant with the international firm of Laventhol & Horwath, he was CFO of Disetronic and Corporate Controller for Diametric Medical Devices. He has also held executive positions with American Express, Capitol Distributions and International Creative Management. Mr. Myers has an MBA in Finance from Adelphi University and a BBA in Public Accounting from Hofstra University.
Mr. Johnson was appointed COO in 2012. Dave has over 35 years experience in executive, operations, and management training positions in rapid growth medical device organizations, directing growth domestically and internationally with products ranging from consumer-based disposable commodity items to class III implantable devices.
Mr. Dauwaulter joined the company in 2008 and has served as the Director of Product Management since 2009. He brings several years of entrepreneurial and sales experience to Skyline. Prior to joining Skyline, he was a founder and owner of a company focusing on infection control with applications in the medical sector. His sales, operational and marketing experience suits the diverse activities for which he is responsible at Skyline.
Mr. Schmidt has over 25 years of experience in the design and development of medical devices. He brings solid expertise in bringing products from concept to manufacturing in this field and aslo has a strong background in pneumatic and pressure design.
2915 Commers Drive
Eagan, MN 55121